Importantly, both sacituzumab govitecan and hRS7-IgG demonstrated significant ADCC against Trop-2 positive cell lines in vitro while negligible ADCC was detected after exposure of the same primary tumor cell lines to the non-targeting control ADC. The gene discussed is TACSTD2; the disease is neoplasm.